Form 4: Brian G. Atwood Acquires Stock Options in Cero Therapeutics Holdings, Inc.

Director Brian G. Atwood acquired stock options in Cero Therapeutics Holdings, Inc. on March 4, 2025.

Summary

• On March 4, 2025, Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., acquired stock options to purchase 14,936 shares of common stock.
• The options have an exercise price of $1.43.
• These options represent the 50% time-based portion of an award of options to purchase 29,871 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions.
• The time-based portion of the options vest on March 3, 2026, and expire on March 3, 2035.
• Following the transaction, Atwood directly owns 14,936 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates confidence from a director.

Key Dates

Keywords

Stock Options, Form 4, Cero Therapeutics Holdings, Brian G. Atwood, Beneficial Ownership, Director